We are live on ! Find out more
LGM

Logos Global Management Portfolio holdings

AUM $2B
1-Year Est. Return 444.09%
This Fund
S&P 500
This Quarter Est. Return
-19.37%
1 Year Est. Return
+444.09%
3 Year Est. Return
+1,593.63%
5 Year Est. Return
+2,146.66%
10 Year Est. Return
–
AUM
$563M
AUM Growth
-$292M
Cap. Flow
-$116M
Cap. Flow %
-20.64%
Top 10 Hldgs %
61.97%
Holding
58
New
11
Increased
10
Reduced
6
Closed
19

Top Buys

Rank Stock Value
1
NUVL
Nuvalent
NUVL
+$39.1M
2
TEVA icon
Teva Pharmaceuticals
TEVA
+$30.4M
3
XENE icon
Xenon Pharmaceuticals
XENE
+$24.7M
4
KROS icon
Keros Therapeutics
KROS
+$23.2M
5
ETNB
89bio
ETNB
+$21.9M

Top Sells

Rank Stock Value
1
CYTK icon
Cytokinetics
CYTK
+$42.3M
2
VERA icon
Vera Therapeutics
VERA
+$37M
3
MRUS
Merus
MRUS
+$31.5M
4
INSM icon
Insmed
INSM
+$31.1M
5
NBIX icon
Neurocrine Biosciences
NBIX
+$27.3M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NBIX icon
51
Neurocrine Biosciences
NBIX
$18.2B
– –
-200,000
Closed -$27.3M
PCVX icon
52
Vaxcyte
PCVX
$7.65B
– –
-300,000
Closed -$24.6M
PLRX icon
53
Pliant Therapeutics
PLRX
$65M
– –
-750,000
Closed -$9.88M
SYRE icon
54
Spyre Therapeutics
SYRE
$8.5B
– –
-500,000
Closed -$11.6M
TVTX icon
55
Travere Therapeutics
TVTX
$5.17B
– –
-1,000,000
Closed -$17.4M
VERA icon
56
Vera Therapeutics
VERA
$2.33B
– –
-875,000
Closed -$37M
YMAB
57
DELISTED
Y-mAbs Therapeutics
YMAB
– –
-1,000,000
Closed -$7.83M
ATYR
58
aTyr Pharma
ATYR
$47.4M
– –
-1,000,000
Closed -$3.62M
1 2
3

Similar funds

MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2B AUM 22.52% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return
LBC
Lowe Brockenbrough & Co Richmond, Virginia $2.01B AUM 22.05% 1-Year Est. Return
C
Consulta London, United Kingdom $2.01B AUM 16.82% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BGM
Burkehill Global Management New York $2.02B AUM 85.32% 1-Year Est. Return
SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
AF
Alerus Financial Grand Forks, North Dakota $2.02B AUM 26.03% 1-Year Est. Return

Logos Global Management's Q1 2025 Portfolio in Review

As of Q1 2025, Logos Global Management held 58 positions worth $563M, down 34% from $855M the previous quarter. Its ten largest holdings account for 62% of the portfolio.

Logos Global Management withdrew a net $116M in Q1 2025, closing 19 positions and reducing 6 holdings. Its most notable exit was Cytokinetics, an estimated $42.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier.

Against the trend, Logos Global Management opened a new position in Nuvalent worth $35.5M.

  • Logos Global Management's largest Q1 2025 buy was Nuvalent: 500,000 shares worth $35.5M.
  • Logos Global Management added most to Akero Therapeutics in Q1 2025, an estimated $17M increase.
  • Logos Global Management's biggest Q1 2025 reduction was BioNTech, cutting an estimated $11.2M.
  • Logos Global Management fully exited Cytokinetics in Q1 2025, selling an estimated $42.3M.
  • Logos Global Management's ten largest holdings make up 62% of its $563M portfolio in Q1 2025.
  • Logos Global Management opened 11 new positions and closed 19 in Q1 2025.
  • Logos Global Management's portfolio value fell 34% quarter-over-quarter to $563M.

Based on Logos Global Management's 13F filing for Q1 2025, filed 15 May 2025.